Apr 25, 2024 8:00am EDT Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
Apr 19, 2024 8:00am EDT Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
Apr 09, 2024 8:00am EDT Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Mar 15, 2024 8:00am EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 21, 2024 8:00am EST Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
Feb 15, 2024 8:00am EST Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
Feb 13, 2024 8:00am EST Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Feb 06, 2024 8:00am EST Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
Jan 31, 2024 8:00am EST Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain